How Could a New Longevity Medicine Create $200B Per Year in Revenue? Dr. Greg Bailey and I asked top VC Alex Colville from age1

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/97/48/6f/97486f51-a3a1-4892-bdd4-7b7dda89bf13/mza_5148514960926470534.jpg/600x600bb.jpg

Longevity for Investors with Dr. Greg Bailey and Jess Larsen

Graystoke Networks

18 episodes

9 months ago

The Longevity for Investors podcast mini-series is co-hosted by Dr. Greg Bailey, Chairman of Juvenescence https://www.drgregbailey.com/ and Jess Larsen. On this series we interview top Longevity experts, CEOs, as well as other interesting High Profile people.

All content for Longevity for Investors with Dr. Greg Bailey and Jess Larsen is the property of Graystoke Networks and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Investing

Business,

Health & Fitness

https://megaphone.imgix.net/podcasts/0a68331e-396c-11ef-95f5-1be2e80c4b37/image/28ad961d9254699af2f6cbf3ac720025.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress

How Could a New Longevity Medicine Create $200B Per Year in Revenue? Dr. Greg Bailey and I asked top VC Alex Colville from age1

Longevity for Investors with Dr. Greg Bailey and Jess Larsen

47 minutes

1 year ago

How Could a New Longevity Medicine Create $200B Per Year in Revenue? Dr. Greg Bailey and I asked top VC Alex Colville from age1

What can we learn from an investor who has deployed over $100 million into longevity-focused biotech startups? Alex Colville shares his biggest takeaways, from the importance of founder-market fit to the need to challenge assumptions in a nascent field.